← Leaderboards
Nancy Gore Saravia
Yale University
$3,661,634
Attributed
$6,572,615
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2011–24$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$9,346,856 · 6
By mechanism
U19$3,676,974 · 3
D43$2,703,064 · 1
R01$2,630,480 · 1
R21$336,338 · 1
Top collaborators
- Christian Tschudi8 shared
- Diane Mcmahon Pratt7 shared
- Eliah S Aronoff-Spencer2 shared
- Mayur Mahesh Desai2 shared
Most similar at Yale University
Same institution · by research overlap
- Diane McMahon Pratt$11,622,683
- Lyda Elena Osorio$727,729
- Dawn Marie Wetzel$3,536,531
- Leonard E Munstermann$4,484,366
- Theodore R Holford$8,685,368
Others in their field
Top investigators on “Leishmaniasis”
- Wilhelmus G. J. Hol · University Of Washington$31,003,173
- Phillip A. Scott · University Of Pennsylvania$23,688,775
- Stephen M Beverley · Washington University$22,938,258
- Mary Edythe Wilson · University Of Iowa$10,364,568
- Diane McMahon Pratt · Yale University$7,903,133
- William H Gerwick · Oregon State University$7,792,712
Research focus
LeishmaniasisBaseInnovationColombiaAreaTraining ProgramsProgramsCutaneous LeishmaniasisResponseUniversitiesCommunicationPoliciesTechnologyResearch PersonnelOnline SystemsEducational WorkshopMonitorInstitutionResearch TrainingDetectionParasitesPharmaceutical PreparationsEvaluationLatin American
Grant awards (32)
Integration of Translational and Implementation Research Training on Leishmaniasis and other Vector-borne and Emerging Infectious Diseases$294,736
D43 · FY2024 · TW · contact PI
Integration of Translational and Implementation Research Training on Leishmaniasis and other Vector-borne and Emerging Infectious Diseases$297,958
D43 · FY2023 · TW · contact PI
Integration of Translational and Implementation Research Training on Leishmaniasis and other Vector-borne and Emerging Infectious Diseases$297,783
D43 · FY2022 · TW · contact PI
Optimizing Surveillance and Treatment for Control of Cutaneous Leishmaniasis$539,134
U19 · FY2021 · AI · contact PI
Integration of Translational and Implementation Research Training on Leishmaniasis and other Vector-borne and Emerging Infectious Diseases$297,940
D43 · FY2021 · TW · contact PI
Parasite Drug Susceptibility in The Response To Anti-Leishmanial Treatment$198,783
U19 · FY2021 · AI · contact PI
Administrative Core$78,446
U19 · FY2021 · AI · contact PI
Integration of Translational and Implementation Research Training on Leishmaniasis and other Vector-borne and Emerging Infectious Diseases$75,000
D43 · FY2021 · TW · contact PI
Optimizing Surveillance and Treatment for Control of Cutaneous Leishmaniasis$552,668
U19 · FY2020 · AI · contact PI
Integration of Translational and Implementation Research Training on Leishmaniasis and other Vector-borne and Emerging Infectious Diseases$299,534
D43 · FY2020 · TW · contact PI
Parasite Drug Susceptibility in The Response To Anti-Leishmanial Treatment$128,300
U19 · FY2020 · AI · contact PI
Administrative Core$37,175
U19 · FY2020 · AI · contact PI
Optimizing Surveillance and Treatment for Control of Cutaneous Leishmaniasis$559,430
U19 · FY2019 · AI · contact PI
Parasite Drug Susceptibility in The Response To Anti-Leishmanial Treatment$129,285
U19 · FY2019 · AI · contact PI
Administrative Core$37,165
U19 · FY2019 · AI · contact PI
Optimizing Surveillance and Treatment for Control of Cutaneous Leishmaniasis$566,695
U19 · FY2018 · AI · contact PI
Translational Research Training on Leishmaniasis & Emerging Infectious Diseases$229,026
D43 · FY2018 · TW
Parasite Drug Susceptibility in The Response To Anti-Leishmanial Treatment$103,494
U19 · FY2018 · AI · contact PI
Administrative Core$41,872
U19 · FY2018 · AI · contact PI
Optimizing Surveillance and Treatment for Control of Cutaneous Leishmaniasis$556,314
U19 · FY2017 · AI · contact PI
Translational Research Training on Leishmaniasis & Emerging Infectious Diseases$227,215
D43 · FY2017 · TW
Applying innovative mobile health technologies to improve diagnosis, treatment and follow-up of patients with leishmaniasis in rural Colombia$162,362
R21 · FY2017 · TW
Parasite Drug Susceptibility in The Response To Anti-Leishmanial Treatment$104,512
U19 · FY2017 · AI · contact PI
Administrative Core$43,701
U19 · FY2017 · AI · contact PI
Translational Research Training on Leishmaniasis & Emerging Infectious Diseases$228,824
D43 · FY2016 · TW
Applying innovative mobile health technologies to improve diagnosis, treatment and follow-up of patients with leishmaniasis in rural Colombia$173,976
R21 · FY2016 · TW
Translational Research Training on Leishmaniasis & Emerging Infectious Diseases$225,829
D43 · FY2015 · TW
Improved Treatment of American Cutaneous Leishmaniasis by Immunomodulation$669,610
R01 · FY2014 · AI
Translational Research Training on Leishmaniasis & Emerging Infectious Diseases$229,219
D43 · FY2014 · TW
Improved Treatment of American Cutaneous Leishmaniasis by Immunomodulation$627,013
R01 · FY2013 · AI
Improved Treatment of American Cutaneous Leishmaniasis by Immunomodulation$661,652
R01 · FY2012 · AI
Improved Treatment of American Cutaneous Leishmaniasis by Immunomodulation$672,205
R01 · FY2011 · AI